[Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
To reduce the future risk of fracture, we recommend that patients treated for fragility fractures (FF) in the OPD be given vitamin D (20 mcg OD) and calcium (1200 mg OD) until the fracture has healed, be counseled on the possible relation of their fracture to osteoporosis (OPO) and contact their GP for examination. Patients with FF of the hip may also be treated with vitamin D and calcium and screened for secondary OPO. If screening tests are negative and life expectancy is greater than two years, a measurement of bone mineral density is not necessary before the start of treatment with bisphosphonate.
Christoffersen
Hardy
H
Sygehus Nord/Thisted, Ortopaedkirurgisk Afdeling. tskirhc@dadlnet.dk
Holmegaard
Stig Nistrup
SN
D000328:Adult; D000368:Aged; D019386:Alendronate / Q000008:administration & dosage; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D002118:Calcium / Q000008:administration & dosage; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D017102:Fracture Healing / Q000187:drug effects; D005598:Fractures, Spontaneous / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control; D006620:Hip Fractures / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D010347:Patient Care Planning; D010353:Patient Education as Topic; D000068296:Risedronic Acid; D014807:Vitamin D / Q000008:administration & dosage
D050071:Bone Density Conservation Agents; D014807:Vitamin D; D000068296:Risedronic Acid; D012968:Etidronic Acid; D002118:Calcium; D019386:Alendronate